Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
Sponsor: AstraZeneca
Summary
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.
Official title: A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)
Key Details
Gender
All
Age Range
18 Years - 130 Years
Study Type
INTERVENTIONAL
Enrollment
1186
Start Date
2017-06-01
Completion Date
2027-11-15
Last Updated
2026-03-13
Healthy Volunteers
No
Conditions
Interventions
Durvalumab
IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until disease progression or other discontinuation criteria
Tremelimumab
IV infusions every 3 weeks for 12 weeks (4 cycles). An additional dose of tremelimumab will be administered in the week 16.
Abraxane + carboplatin
Standard of care chemotherapy (squamous and non-squamous patients): Abraxane 100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle. Carboplatin Area under the plasma drug concentration-time curve (AUC) 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
Gemcitabine + cisplatin
Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
Gemcitabine + carboplatin
Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
Pemetrexed + carboplatin
Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\] until objective disease progression.
Pemetrexed + cisplatin
Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\] until objective disease progression.
Locations (175)
Research Site
Phoenix, Arizona, United States
Research Site
Bakersfield, California, United States
Research Site
Santa Monica, California, United States
Research Site
Fort Myers, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
St. Petersburg, Florida, United States
Research Site
West Palm Beach, Florida, United States
Research Site
Louisville, Kentucky, United States
Research Site
Kansas City, Missouri, United States
Research Site
Canton, Ohio, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Chattanooga, Tennessee, United States
Research Site
Nashville, Tennessee, United States
Research Site
Fort Worth, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Richmond, Virginia, United States
Research Site
Barretos, Brazil
Research Site
Belo Horizonte, Brazil
Research Site
Curitiba, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Ribeirão Preto, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Santo André, Brazil
Research Site
Santo André, Brazil
Research Site
São José do Rio Preto, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Plovdiv, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Varna, Bulgaria
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Changchun, China
Research Site
Changsha, China
Research Site
Fuzhou, China
Research Site
Guangzhou, China
Research Site
Hangzhou, China
Research Site
Harbin, China
Research Site
Hefei, China
Research Site
Kunming, China
Research Site
Linyi, China
Research Site
Liuchow, China
Research Site
Nanjing, China
Research Site
Qingdao, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shantou, China
Research Site
Wuhan, China
Research Site
Wuhan, China
Research Site
Xining, China
Research Site
Yangzhou, China
Research Site
Zhanjiang, China
Research Site
Zhengzhou, China
Research Site
Zhengzhou, China
Research Site
Berlin, Germany
Research Site
Essen, Germany
Research Site
Freiburg im Breisgau, Germany
Research Site
Gauting, Germany
Research Site
Hamburg, Germany
Research Site
Hamburg, Germany
Research Site
Heidelberg, Germany
Research Site
Immenhausen, Germany
Research Site
Mainz, Germany
Research Site
Oldenburg, Germany
Research Site
Würzburg, Germany
Research Site
Shatin, Hong Kong
Research Site
Budapest, Hungary
Research Site
Budapest, Hungary
Research Site
Kecskemét, Hungary
Research Site
Miskolc, Hungary
Research Site
Törökbálint, Hungary
Research Site
Bunkyō City, Japan
Research Site
Chūōku, Japan
Research Site
Fukuoka, Japan
Research Site
Hiroshima, Japan
Research Site
Iwakuni-shi, Japan
Research Site
Kanazawa, Japan
Research Site
Kashiwa, Japan
Research Site
Kōtoku, Japan
Research Site
Kurume-shi, Japan
Research Site
Matsuyama, Japan
Research Site
Okayama, Japan
Research Site
Okayama, Japan
Research Site
Sapporo, Japan
Research Site
Sayama, Japan
Research Site
Sunto-gun, Japan
Research Site
Toyoake-shi, Japan
Research Site
Ube-shi, Japan
Research Site
Yokohama, Japan
Research Site
Yokohama, Japan
Research Site
Aguascalientes, Mexico
Research Site
Cuautitlán Izcalli, Mexico
Research Site
Guadalajara, Mexico
Research Site
Mexico City, Mexico
Research Site
México, Mexico
Research Site
México, Mexico
Research Site
Monterrey, Mexico
Research Site
Monterrey, Mexico
Research Site
Tuxtla Gutiérrez, Mexico
Research Site
Arequipa, Peru
Research Site
Lima, Peru
Research Site
Lima, Peru
Research Site
Lima, Peru
Research Site
Lima, Peru
Research Site
San Isidro, Peru
Research Site
Olsztyn, Poland
Research Site
Tomaszów Mazowiecki, Poland
Research Site
Warsaw, Poland
Research Site
Wodzisław Śląski, Poland
Research Site
Moscow, Russia
Research Site
Moscow, Russia
Research Site
Moscow, Russia
Research Site
Moscow, Russia
Research Site
Omsk, Russia
Research Site
Saint Petersburg, Russia
Research Site
Saint Petersburg, Russia
Research Site
Saint Petersburg, Russia
Research Site
Saint Petersburg, Russia
Research Site
Cape Town, South Africa
Research Site
Durban, South Africa
Research Site
Johannesburg, South Africa
Research Site
Parktown, South Africa
Research Site
Pretoria, South Africa
Research Site
Rondebosch, South Africa
Research Site
Vereeniging, South Africa
Research Site
Busan, South Korea
Research Site
Chungcheongbuk-do, South Korea
Research Site
Daegu, South Korea
Research Site
Incheon, South Korea
Research Site
Seongnam-si, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Ulsan, South Korea
Research Site
Changhua, Taiwan
Research Site
Kaohsiung City, Taiwan
Research Site
Kaohsiung City, Taiwan
Research Site
Taichung, Taiwan
Research Site
Taichung, Taiwan
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taoyuan District, Taiwan
Research Site
Bangkok, Thailand
Research Site
Bangkok, Thailand
Research Site
Bangkok, Thailand
Research Site
Muang, Thailand
Research Site
Songkhla, Thailand
Research Site
Dnipro, Ukraine
Research Site
Ivano-Frankivsk, Ukraine
Research Site
Kirovohrad, Ukraine
Research Site
Kyiv, Ukraine
Research Site
Kyiv, Ukraine
Research Site
Lviv, Ukraine
Research Site
Odesa, Ukraine
Research Site
Sumy, Ukraine
Research Site
Vinnytsia, Ukraine
Research Site
Zaporizhzhia, Ukraine
Research Site
Leicester, United Kingdom
Research Site
London, United Kingdom
Research Site
London, United Kingdom
Research Site
London, United Kingdom
Research Site
Manchester, United Kingdom
Research Site
Hanoi, Vietnam
Research Site
Ho Chi Minh City, Vietnam